274 related articles for article (PubMed ID: 30066936)
1. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
[TBL] [Abstract][Full Text] [Related]
2. Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.
Kitayama K; Kawamoto T; Kawakami Y; Hara H; Takemori T; Fujiwara S; Yahiro S; Miyamoto T; Mifune Y; Hoshino Y; Kakutani K; Matsumoto T; Matsushita T; Niikura T; Kuroda R; Akisue T
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34713296
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
4. Reoxygenation using a novel CO2 therapy decreases the metastatic potential of osteosarcoma cells.
Harada R; Kawamoto T; Ueha T; Minoda M; Toda M; Onishi Y; Fukase N; Hara H; Sakai Y; Miwa M; Kuroda R; Kurosaka M; Akisue T
Exp Cell Res; 2013 Aug; 319(13):1988-1997. PubMed ID: 23727023
[TBL] [Abstract][Full Text] [Related]
5. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
6. Transcutaneous carbon dioxide induces mitochondrial apoptosis and suppresses metastasis of oral squamous cell carcinoma in vivo.
Takeda D; Hasegawa T; Ueha T; Imai Y; Sakakibara A; Minoda M; Kawamoto T; Minamikawa T; Shibuya Y; Akisue T; Sakai Y; Kurosaka M; Komori T
PLoS One; 2014; 9(7):e100530. PubMed ID: 24988190
[TBL] [Abstract][Full Text] [Related]
7. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
[No Abstract] [Full Text] [Related]
8. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
9. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
10. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
[TBL] [Abstract][Full Text] [Related]
12. Transcutaneous carbon dioxide suppresses epithelial-mesenchymal transition in oral squamous cell carcinoma.
Iwata E; Hasegawa T; Takeda D; Ueha T; Kawamoto T; Akisue T; Sakai Y; Komori T
Int J Oncol; 2016 Apr; 48(4):1493-8. PubMed ID: 26846904
[TBL] [Abstract][Full Text] [Related]
13. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
14. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
15. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
16. Cryoprotective isoliquiritigenin-zein phosphatidylcholine nanoparticles inhibits breast cancer-bone metastasis by targeting JAK-STAT signaling pathways.
Ganesan K; Xu C; Xie C; Sui Y; Zheng C; Gao F; Chen J
Chem Biol Interact; 2024 Jun; 396():111037. PubMed ID: 38719172
[TBL] [Abstract][Full Text] [Related]
17. Transcutaneous application of CO2 enhances the antitumor effect of radiation therapy in human malignant fibrous histiocytoma.
Onishi Y; Akisue T; Kawamoto T; Ueha T; Hara H; Toda M; Harada R; Minoda M; Morishita M; Sasaki R; Nishida K; Kuroda R; Kurosaka M
Int J Oncol; 2014 Aug; 45(2):732-8. PubMed ID: 24889546
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
19. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
